State of New Jersey Common Pension Fund D Buys 223 Shares of Intra-Cellular Therapies, Inc. (NASDAQ:ITCI)

State of New Jersey Common Pension Fund D grew its position in shares of Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) by 0.6% during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 35,673 shares of the biopharmaceutical company’s stock after buying an additional 223 shares during the quarter. State of New Jersey Common Pension Fund D’s holdings in Intra-Cellular Therapies were worth $2,610,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors and hedge funds have also recently modified their holdings of the company. Oak Ridge Investments LLC bought a new position in Intra-Cellular Therapies in the second quarter valued at about $811,000. SG Americas Securities LLC grew its position in Intra-Cellular Therapies by 962.7% during the second quarter. SG Americas Securities LLC now owns 48,778 shares of the biopharmaceutical company’s stock valued at $3,341,000 after buying an additional 44,188 shares during the period. Clearbridge Investments LLC increased its holdings in Intra-Cellular Therapies by 12.3% during the first quarter. Clearbridge Investments LLC now owns 1,744,551 shares of the biopharmaceutical company’s stock valued at $120,723,000 after buying an additional 191,416 shares during the last quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. bought a new position in Intra-Cellular Therapies in the first quarter worth approximately $18,379,000. Finally, Russell Investments Group Ltd. boosted its stake in shares of Intra-Cellular Therapies by 232.0% during the 1st quarter. Russell Investments Group Ltd. now owns 50,845 shares of the biopharmaceutical company’s stock worth $3,519,000 after acquiring an additional 35,528 shares during the last quarter. 92.33% of the stock is currently owned by hedge funds and other institutional investors.

Insider Buying and Selling

In other Intra-Cellular Therapies news, EVP Mark Neumann sold 18,714 shares of the stock in a transaction on Friday, August 16th. The shares were sold at an average price of $75.08, for a total transaction of $1,405,047.12. Following the completion of the transaction, the executive vice president now owns 29,700 shares in the company, valued at $2,229,876. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. In other news, EVP Mark Neumann sold 18,714 shares of Intra-Cellular Therapies stock in a transaction that occurred on Friday, August 16th. The stock was sold at an average price of $75.08, for a total value of $1,405,047.12. Following the completion of the transaction, the executive vice president now owns 29,700 shares in the company, valued at approximately $2,229,876. The trade was a 0.00 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Sharon Mates sold 28,680 shares of the stock in a transaction on Friday, August 23rd. The shares were sold at an average price of $74.46, for a total value of $2,135,512.80. Following the sale, the chief executive officer now owns 1,070,329 shares in the company, valued at $79,696,697.34. The trade was a 0.00 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 175,316 shares of company stock worth $13,037,345. Insiders own 2.60% of the company’s stock.

Intra-Cellular Therapies Stock Down 0.3 %

ITCI opened at $88.22 on Thursday. The company has a market capitalization of $9.35 billion, a PE ratio of -101.40 and a beta of 0.97. The firm has a 50-day simple moving average of $77.77 and a two-hundred day simple moving average of $74.12. Intra-Cellular Therapies, Inc. has a 52 week low of $54.17 and a 52 week high of $93.45.

Intra-Cellular Therapies (NASDAQ:ITCI) last released its quarterly earnings results on Wednesday, October 30th. The biopharmaceutical company reported ($0.25) earnings per share for the quarter, missing the consensus estimate of ($0.18) by ($0.07). The firm had revenue of $175.40 million for the quarter, compared to analysts’ expectations of $172.30 million. Intra-Cellular Therapies had a negative net margin of 14.07% and a negative return on equity of 9.93%. The business’s quarterly revenue was up 39.0% compared to the same quarter last year. During the same quarter in the prior year, the business earned ($0.25) EPS. As a group, sell-side analysts expect that Intra-Cellular Therapies, Inc. will post -0.64 earnings per share for the current year.

Wall Street Analysts Forecast Growth

ITCI has been the topic of a number of recent research reports. JPMorgan Chase & Co. raised their target price on Intra-Cellular Therapies from $81.00 to $89.00 and gave the stock an “overweight” rating in a report on Monday, November 4th. Morgan Stanley lifted their price objective on Intra-Cellular Therapies from $92.00 to $95.00 and gave the company an “overweight” rating in a research report on Friday, October 11th. UBS Group reduced their target price on shares of Intra-Cellular Therapies from $83.00 to $79.00 and set a “neutral” rating for the company in a report on Thursday, August 8th. Needham & Company LLC reaffirmed a “buy” rating and set a $100.00 price target on shares of Intra-Cellular Therapies in a report on Wednesday, October 30th. Finally, Piper Sandler raised shares of Intra-Cellular Therapies from a “neutral” rating to an “overweight” rating and increased their price objective for the stock from $68.00 to $92.00 in a research note on Friday, September 6th. Two investment analysts have rated the stock with a hold rating and eleven have given a buy rating to the company. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $97.23.

Intra-Cellular Therapies Company Profile

Intra-Cellular Therapies, Inc, a biopharmaceutical company, focuses on the discovery, clinical development, and commercialization of small molecule drugs that address medical needs primarily in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms in the central nervous system (CNS) in the United States.